Insights
Search Results
Newsletters
6.03.26
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Client Highlights
9.30.25
Wilson Sonsini Advises Assort Health on $76 Million Series B
On September 30, 2025, Assort Health, a comprehensive patient experience platform powered by specialty-specific agentic AI, announced the close of a $76 million Series B financing round led by Lightspeed Venture Partners, with investments by Felicis, First Round Capital, Chemistry, A*, Liquid2, and Quiet. A Wilson Sonsini Goodrich & Rosati team led by Lang Liu, Alex Youssef, and Andrew Lu advised Assort Health on the transaction.
Client Highlights
3.04.25
Wilson Sonsini Advises Infiniti Medical on Employee Benefit and Employment Matters Related to Acquisition by Creative Science
On March 3, 2025, Creative Science, a CIMA Animal Health company, and a leader in veterinary medical solutions, announced the acquisition of Infiniti Medical and its subsidiary Orthomed UK, two globally recognized brands specializing in veterinary interventional radiology, cardiology, soft tissue surgery, and orthopedics. Wilson Sonsini Goodrich & Rosati advised Infiniti Medical on employee benefit and compensation and employment matters related to the transaction.
Client Highlights
12.19.24
Wilson Sonsini Advises Featurespace on Merger with Visa
Wilson Sonsini is pleased to have represented Featurespace as the lead advisor in its recently completed acquisition by Visa. Featurespace is a developer of real-time AI payments protection technology that prevents and mitigates payments fraud and financial crime risks.
Client Highlights
10.15.24
Wilson Sonsini Advises Movet on $5 Million Series A
On October 10, 2024, Colombia-based Movet, a veterinary network, announced that it successfully completed a $5 million Series A financing. The round was led by Wivet. Wilson Sonsini Goodrich & Rosati advised Movet on the transaction.
Client Highlights
3.26.24
Wilson Sonsini Advises Loyal on Patent Matters Related to $45 Million Series B
On March 21, 2024, Loyal for Dogs (Loyal), a biotech company pioneering longevity drugs for dogs, announced the completion of a $45 million Series B funding round led by Bain Capital Ventures. Wilson Sonsini Goodrich & Rosati advised Loyal on patent matters related to the Series B and represents the company in patent strategy and prosecution matters.
Client Highlights
12.01.23
Wilson Sonsini Advises Rover on $2.3 Billion Acquisition by Blackstone
On November 29, 2023, Blackstone Inc. announced the acquisition of Rover Group Inc., the world’s largest online marketplace for pet care, in an all-cash deal worth $2.3 billion. Wilson Sonsini Goodrich & Rosati advised Rover on the transaction.
Alerts
11.03.23
Off-Label Communications Back in the Spotlight at the FDA
For the first time in almost 10 years, the U.S. Food and Drug Administration (FDA) released a draft guidance related to certain communications by firms to healthcare providers (HCPs) of scientific information on unapproved use(s) (SIUU) of approved or cleared medical products. The October 23, 2023, draft guidance, “Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers Guidance for Industry,” relates to communications including published scientific or medical journal articles (also known as reprints), published clinical resources such as clinical practice guidelines (CPGs), and firm-generated presentations of scientific information from an accompanying published reprint. Most notably, the draft guidance provides recommendations and considerations for digital publications and social media.
Client Highlights
8.31.23
Wilson Sonsini Pro Bono Client Revive & Restore Successfully Advocates for New Vaccine Testing Alternative to Horseshoe Crab Blood
On August 22, 2023, the U.S. Pharmacopeia (USP) announced a long-awaited new regulatory chapter, known as Chapter <86>, which provides guidance on endotoxin testing using recombinant Factor C (rFC), a synthetic alternative to blood cells extracted from endangered horseshoe crabs. rFC can be developed at scale and eliminates the need for harvesting (bleeding) horseshoe crabs. The chapter reinforces the work of Wilson Sonsini client Revive & Restore, whose science-based campaign highlighted the efficacy and safety of the recombinant product for endotoxin testing.
Newsletters
6.07.23
The Life Sciences Report – June 2023
This latest issue features an article on Enliven Therapeutics’ reverse merger with Imara and concurrent financing, including an interview with Enliven co-founder and CEO Sam Kintz; a piece on trends in digital health following the end of the COVID-19 public health emergency; and an analysis of life sciences venture financings in which clients participated across the first and second halves of 2022. It also includes details on the life sciences-focused NextGen VC Forum hosted by Wilson Sonsini and LaunchBio, a preview of the U.S.-Japan Healthcare Connection’s trade mission and roadshow for healthcare companies, a recap of the firm’s inaugural 1L Life Sciences Summit, and select life sciences client highlights, among other content.
Alerts
6.05.23
FDA Accelerates Approval of Animals with Investigational Intentional Genomic Alterations (IGAs)
The U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) is advancing ahead in growing the regulatory landscape for developers and sponsors of animals with investigational intentional genomic alterations (IGAs).